Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Cardiovascular Medicine

CME

The Role of Angiotensin Receptor Blockade in the Treatment of Heart Failure

This month, Frank A. Laws, M.D., and Richard W. Smalling, M.D., Ph.D., discuss

CME credit is no longer available for this conference.

Course Authors

Frank A. Laws, M.D., and Richard W. Smalling, M.D., Ph.D.

Dr. Laws is a Fellow in the Department of Internal Medicine, Division of Cardiology, University of Texas-Houston Medical School.

Dr. Laws reports no commercial conflict of interest. Dr. Smalling has received grant/research support from Centocor/Boston Scientific within the last three years.

This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Identify why blockade of the renin-angiotensin aldosterone system (RAAS) confers a beneficial effect in patients with congestive heart failure

  • Identify pathways involved in the production of angiotensin-II and receptors that mediate the effects of angiotensin-II

  • List the objectives of ongoing clinical trials assessing the role of ARBs in the treatment of patients with congestive heart failure.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Current Management of Hypertension

The link between elevated blood pressure and cardiovascular disease is firmly established. How to treat HBP is less certain.
Authors: Aditya Khetan, M.B.B.S., Richard A Josephson, M.S., M.D. and Sri Krishna Madan Mohan M.B.B.S.
Estimated Time: 1 Hour
View Course
More

Myocardial Infarction

Significant progress has been made in the primary and secondary prevention of myocardial infarction, but it remains a leading cause of death.
Authors: Richard Josephson, M.S., M.D., and Sri K. Madan Mohan, M.D.
Estimated Time: 1 Hour
View Course
More

Management of Non-Valvular Atrial Fibrillation – The New Era of Oral Anticoagulants

The most important feature which distinguishes AF from other atrial arrhythmias is the absence of P waves.
Authors: Muhib Khan, M.D., and Karen Furie, M.D., M.P.H.
Estimated Time: 2 Hours
View Course
More

Current Management of Acute Decompensated Heart Failure

The rate of hospitalization for acute decompensated heart failure will continue to increase because of an aging population.
Authors: Joel Schilling, M.D., Ph.D.
Estimated Time: 1 Hour
View Course
More

Pharmacological Therapy of Cardiac Arrhythmias: Atrial Fibrillation, Current Treatment and Novel Agents

Cardiac arrhythmias may be seen in individuals with known cardiovascular disease (i.e., coronary artery disease (CAD) or valvular abnormalities) or even in those without known cardiac illnesses. The spectrum of cardiac arrhythmias varies between more self-limited or minimally symptomatic findings such as palpitations, which may be associated with premature supraventricular or ventricular beats that many experience, to the more worrisome ventricular fibrillation, a known cause of sudden cardiac arrest for which emergency cardiac resuscitation is required. of cardiac arrhythmias varies between more self-limited or minimally symptomatic findings such as palpitations, which may be associated with premature supraventricular or ventricular beats that many experience, to the more worrisome ventricular fibrillation, a known cause of sudden cardiac arrest for which emergency cardiac resuscitation is required.
Authors: Mohan N. Viswanathan, M.D.
Estimated Time: 1 Hour
View Course
More

Cardiac Vagal Neurostimulation for Ventricular Rate Control During Atrial Fibrillation

There are two broad strategic treatment options for AF treatment: rhythm control and rate control.
Authors: Youhua Zhang, M.D., Ph.D., and Todor N. Mazgalev, Ph.D.
Estimated Time: 1 Hour
View Course
More